Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_assertion description "[Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_assertion evidence source_evidence_literature NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_assertion SIO_000772 24646054 NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_assertion wasDerivedFrom befree-20150227 NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_assertion wasGeneratedBy ECO_0000203 NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.
- befree-20150227 importedOn "2015-02-27" NP380808.RARgTX-WwZuIU6tq0EWI6nD9rDZEBtjwQH1ITlfH4-bIc130_provenance.